Great Point Partners as of Sept. 30, 2024
Portfolio Holdings for Great Point Partners
Great Point Partners holds 29 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Neurogene (NGNE) | 12.4 | $42M | 1.0M | 41.96 | |
| Abivax Sa Sponsored Ads (ABVX) | 7.2 | $25M | 2.1M | 11.52 | |
| Pliant Therapeutics (PLRX) | 6.3 | $21M | 1.9M | 11.21 | |
| Evolus (EOLS) | 5.6 | $19M | 1.2M | 16.20 | |
| Miragen Therapeutics (VRDN) | 5.0 | $17M | 750k | 22.75 | |
| Arcellx Common Stock (ACLX) | 4.9 | $17M | 200k | 83.51 | |
| Cytokinetics Com New (CYTK) | 4.9 | $17M | 316k | 52.80 | |
| Kalvista Pharmaceuticals (KALV) | 4.4 | $15M | 1.3M | 11.58 | |
| Dynavax Technologies Corp Com New (DVAX) | 4.3 | $15M | 1.3M | 11.14 | |
| Context Therapeutics (CNTX) | 4.0 | $14M | 6.9M | 1.96 | |
| Zura Bio Class A Ord Shs (ZURA) | 3.9 | $13M | 3.3M | 4.06 | |
| Oruka Therapeutics (ORKA) | 3.7 | $13M | 515k | 24.51 | |
| Merus N V (MRUS) | 3.7 | $13M | 250k | 49.96 | |
| Olema Pharmaceuticals (OLMA) | 3.5 | $12M | 1.0M | 11.94 | |
| Ionis Pharmaceuticals (IONS) | 3.0 | $10M | 255k | 40.06 | |
| Autolus Therapeutics Spon Ads (AUTL) | 3.0 | $10M | 2.8M | 3.63 | |
| Urogen Pharma (URGN) | 2.8 | $9.6M | 759k | 12.70 | |
| Optinose | 2.5 | $8.6M | 13M | 0.67 | |
| Dianthus Therapeutics (DNTH) | 2.2 | $7.5M | 275k | 27.38 | |
| Outlook Therapeutics (OTLK) | 2.0 | $6.9M | 1.3M | 5.34 | |
| Jasper Therapeutics Com New (JSPR) | 1.8 | $6.1M | 322k | 18.81 | |
| Voyager Therapeutics (VYGR) | 1.7 | $5.6M | 960k | 5.85 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.5 | $5.2M | 500k | 10.45 | |
| Tscan Therapeutics (TCRX) | 1.5 | $5.1M | 1.0M | 4.98 | |
| Unicycive Therapeutics | 1.0 | $3.5M | 8.6M | 0.41 | |
| Promis Neurosciences Com New (PMN) | 1.0 | $3.5M | 2.8M | 1.25 | |
| Cartesian Therapeutics Com New (RNAC) | 0.9 | $3.2M | 200k | 16.12 | |
| Vistagen Therapeutics Ord (VTGN) | 0.6 | $2.0M | 674k | 3.01 | |
| Eliem Therapeutics (CLYM) | 0.4 | $1.3M | 248k | 5.09 |
